US-localized diffuse optical tomography in breast cancer: Comparison with pharmacokinetic parameters of DCE-MRI and with pathologic biomarkers

Min Jung Kim, Min Ying Su, Hon J. Yu, Jeon Hor Chen, Eun Kyung Kim, Hee Jung Moon, Ji Soo Choi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: To correlate parameters of Ultrasonography-guided Diffuse optical tomography (US-DOT) with pharmacokinetic features of Dynamic contrast-enhanced (DCE)-MRI and pathologic markers of breast cancer. Methods: Our institutional review board approved this retrospective study and waived the requirement for informed consent. Thirty seven breast cancer patients received US-DOT and DCE-MRI with less than two weeks in between imaging sessions. The maximal total hemoglobin concentration (THC) measured by US-DOT was correlated with DCE-MRI pharmacokinetic parameters, which included K trans , k ep and signal enhancement ratio (SER). These imaging parameters were also correlated with the pathologic biomarkers of breast cancer. Results: The parameters THC and SER showed marginal positive correlation (r = 0.303, p = 0.058). Tumors with high histological grade, negative ER, and higher Ki-67 expression ≥20 % showed statistically higher THC values compared to their counterparts (p = 0.019, 0.041, and 0.023 respectively). Triple-negative (TN) breast cancers showed statistically higher K trans values than non-TN cancers (p = 0.048). Conclusion: THC obtained from US-DOT and K trans obtained from DCE-MRI were associated with biomarkers indicative of a higher aggressiveness in breast cancer. Although US-DOT and DCE-MRI both measured the vascular properties of breast cancer, parameters from the two imaging modalities showed a weak association presumably due to their different contrast mechanisms and depth sensitivities.

Original languageEnglish
Article number50
JournalBMC cancer
Volume16
Issue number1
DOIs
Publication statusPublished - 2016 Feb 1

Fingerprint

Optical Tomography
Ultrasonography
Pharmacokinetics
Biomarkers
Breast Neoplasms
Hemoglobins
Triple Negative Breast Neoplasms
Research Ethics Committees
Informed Consent
Blood Vessels
Neoplasms
Retrospective Studies

All Science Journal Classification (ASJC) codes

  • Genetics
  • Oncology
  • Cancer Research

Cite this

@article{540e66911b614f5b884a3913a4cc054f,
title = "US-localized diffuse optical tomography in breast cancer: Comparison with pharmacokinetic parameters of DCE-MRI and with pathologic biomarkers",
abstract = "Background: To correlate parameters of Ultrasonography-guided Diffuse optical tomography (US-DOT) with pharmacokinetic features of Dynamic contrast-enhanced (DCE)-MRI and pathologic markers of breast cancer. Methods: Our institutional review board approved this retrospective study and waived the requirement for informed consent. Thirty seven breast cancer patients received US-DOT and DCE-MRI with less than two weeks in between imaging sessions. The maximal total hemoglobin concentration (THC) measured by US-DOT was correlated with DCE-MRI pharmacokinetic parameters, which included K trans , k ep and signal enhancement ratio (SER). These imaging parameters were also correlated with the pathologic biomarkers of breast cancer. Results: The parameters THC and SER showed marginal positive correlation (r = 0.303, p = 0.058). Tumors with high histological grade, negative ER, and higher Ki-67 expression ≥20 {\%} showed statistically higher THC values compared to their counterparts (p = 0.019, 0.041, and 0.023 respectively). Triple-negative (TN) breast cancers showed statistically higher K trans values than non-TN cancers (p = 0.048). Conclusion: THC obtained from US-DOT and K trans obtained from DCE-MRI were associated with biomarkers indicative of a higher aggressiveness in breast cancer. Although US-DOT and DCE-MRI both measured the vascular properties of breast cancer, parameters from the two imaging modalities showed a weak association presumably due to their different contrast mechanisms and depth sensitivities.",
author = "Kim, {Min Jung} and Su, {Min Ying} and Yu, {Hon J.} and Chen, {Jeon Hor} and Kim, {Eun Kyung} and Moon, {Hee Jung} and Choi, {Ji Soo}",
year = "2016",
month = "2",
day = "1",
doi = "10.1186/s12885-016-2086-7",
language = "English",
volume = "16",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",
number = "1",

}

US-localized diffuse optical tomography in breast cancer : Comparison with pharmacokinetic parameters of DCE-MRI and with pathologic biomarkers. / Kim, Min Jung; Su, Min Ying; Yu, Hon J.; Chen, Jeon Hor; Kim, Eun Kyung; Moon, Hee Jung; Choi, Ji Soo.

In: BMC cancer, Vol. 16, No. 1, 50, 01.02.2016.

Research output: Contribution to journalArticle

TY - JOUR

T1 - US-localized diffuse optical tomography in breast cancer

T2 - Comparison with pharmacokinetic parameters of DCE-MRI and with pathologic biomarkers

AU - Kim, Min Jung

AU - Su, Min Ying

AU - Yu, Hon J.

AU - Chen, Jeon Hor

AU - Kim, Eun Kyung

AU - Moon, Hee Jung

AU - Choi, Ji Soo

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Background: To correlate parameters of Ultrasonography-guided Diffuse optical tomography (US-DOT) with pharmacokinetic features of Dynamic contrast-enhanced (DCE)-MRI and pathologic markers of breast cancer. Methods: Our institutional review board approved this retrospective study and waived the requirement for informed consent. Thirty seven breast cancer patients received US-DOT and DCE-MRI with less than two weeks in between imaging sessions. The maximal total hemoglobin concentration (THC) measured by US-DOT was correlated with DCE-MRI pharmacokinetic parameters, which included K trans , k ep and signal enhancement ratio (SER). These imaging parameters were also correlated with the pathologic biomarkers of breast cancer. Results: The parameters THC and SER showed marginal positive correlation (r = 0.303, p = 0.058). Tumors with high histological grade, negative ER, and higher Ki-67 expression ≥20 % showed statistically higher THC values compared to their counterparts (p = 0.019, 0.041, and 0.023 respectively). Triple-negative (TN) breast cancers showed statistically higher K trans values than non-TN cancers (p = 0.048). Conclusion: THC obtained from US-DOT and K trans obtained from DCE-MRI were associated with biomarkers indicative of a higher aggressiveness in breast cancer. Although US-DOT and DCE-MRI both measured the vascular properties of breast cancer, parameters from the two imaging modalities showed a weak association presumably due to their different contrast mechanisms and depth sensitivities.

AB - Background: To correlate parameters of Ultrasonography-guided Diffuse optical tomography (US-DOT) with pharmacokinetic features of Dynamic contrast-enhanced (DCE)-MRI and pathologic markers of breast cancer. Methods: Our institutional review board approved this retrospective study and waived the requirement for informed consent. Thirty seven breast cancer patients received US-DOT and DCE-MRI with less than two weeks in between imaging sessions. The maximal total hemoglobin concentration (THC) measured by US-DOT was correlated with DCE-MRI pharmacokinetic parameters, which included K trans , k ep and signal enhancement ratio (SER). These imaging parameters were also correlated with the pathologic biomarkers of breast cancer. Results: The parameters THC and SER showed marginal positive correlation (r = 0.303, p = 0.058). Tumors with high histological grade, negative ER, and higher Ki-67 expression ≥20 % showed statistically higher THC values compared to their counterparts (p = 0.019, 0.041, and 0.023 respectively). Triple-negative (TN) breast cancers showed statistically higher K trans values than non-TN cancers (p = 0.048). Conclusion: THC obtained from US-DOT and K trans obtained from DCE-MRI were associated with biomarkers indicative of a higher aggressiveness in breast cancer. Although US-DOT and DCE-MRI both measured the vascular properties of breast cancer, parameters from the two imaging modalities showed a weak association presumably due to their different contrast mechanisms and depth sensitivities.

UR - http://www.scopus.com/inward/record.url?scp=84957970429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957970429&partnerID=8YFLogxK

U2 - 10.1186/s12885-016-2086-7

DO - 10.1186/s12885-016-2086-7

M3 - Article

C2 - 26833069

AN - SCOPUS:84957970429

VL - 16

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 50

ER -